Hrt: decide based on the evidence

Nurse Practitioner

Volumn 28, Issue 9, 2003, Pages 46-54

  Lookinland, Sandra ^a   Beckstrand, Renea L ^b  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST TUMOR; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DECISION MAKING; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; NURSING; NURSING RESEARCH; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIMARY PREVENTION; REVIEW;

BREAST NEOPLASMS; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; DECISION MAKING; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; NURSING RESEARCH; OSTEOPOROSIS, POSTMENOPAUSAL; PRACTICE GUIDELINES; PRIMARY PREVENTION;

EID: 0242348812     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/00006205-200309000-00007     Document Type: Article

References (63)

1. Cyr MG: Postmenopausal hormone therapy in the aftermath of the WHI. Postgrad Med Mar 2003; 113(3):15-18, 20.
2. Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288:321-333.
3. Goodman N, Goldzieher J, Ayala C: Critique of the report from the writing group of the WHI. Menopausal Med 2003; 10(4):1-7.
4. Wenger NK: Editoral. In: Wenger NK, Mosca, L, Collins, R, et al: The importance of identifying and reducing cardiovascular risk factors in women. CME. WebMD Medscape Release date: February 21, 2003. Found at. Accessed July 31, 2003.
5. U. S. Preventive Services Task Force: Guide to Clinical Preventive Services. 2nd ed. Baltimore:Williams & Wilkins; 1996.
6. USPSTF HRT recommendations: Available at:. Accessed October 15, 2002.
7. Nelson HD, Humphrey LL, LeBlanc E, et al.: Postmenopausal hormone replacement therapy for primary prevention of chronic conditions. Available at:. Accessed October 2, 2002.
8. Manson JE, Hsia J, Johnson KC: Estrogen plus progestin and the risk of coronary heart disease. N Eng J Med 2003; 349 (6) 523-534.
9. National Heart, Lung & Blood Institute: Statement from Claude Lenfant, MD, NHLBI Director, on preliminary trends in Women’s Health Initiative. Bethesda, Maryland: National Heart, Lung & Blood Institute: April 3, 2000.
10. Wenger NK: Menopausal hormone therapy and risk for cardiovascular disease: current status. In: Wenger NK, Mosca, L, Collins, R, Oparil S, Blumenthal RS: The importance of identifying and reducing cardiovascular risk factors in women. CME. WebMD Medscape. Release date: February 21, 2003.
11. Mueck AO, Seeger H: Smoking, estradiol metabolism and hormone replacement therapy. Arzneimittel-Forschung 2003; 53(1):1-11.
12. Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 208(7):605.613.
13. Grady D, Herrington D, Bittner V, et al.: Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA 2002; 288:49-57.
14. Wenger NK, Knatterud GL, Canner PL: Early risks of hormone therapy in patients with coronary heart disease. JAMA 2000; 284:41-43.
15. Sourander L, Rajala T, Raiha I, et al.: Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on estrogen replacement therapy (ERT). Lancet 1998; 352:1965-1969.
16. Grodstein F, Stampfer MJ, Colditz GA, et al.: Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336(25):1769-1775.
17. Bush TL, Barrett-Connor E, Cowan LD, et al.: Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75(6):1102-1109.
18. Petitti DB, Perlman JA, Sidney S.: Noncontraceptive estrogens and mortality: Long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987; 70(3 Pt 1):289-293.
19. Cauley JA, Seeley DG, Browner WS, et al.: Estrogen replacement therapy and mortality among older women: The study of osteoporotic fractures. Arch Intern Med 1997; 157(19):2181-2187.
20. Folsom AR, Mink PJ, Sellers TA, et al.: Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995; 85(8 Pt. 1):1128-1132.
21. Fung MM, Barrett-Connor E, Bettencourt RR.: Hormone replacement therapy and stroke risk in older women. J Womens Health 1999; 8(3):359-364.
22. Finucane FF, Madans JH, Bush TL, et al.: Decreased risk of stroke among postmenopausal hormone users: Results from a national cohort. Arch Intern Med 1993; 153(1):73-79.
23. Rodriguez C, Calle EE, Patel AV, et al.: Effect of body mass on the association between estrogen replacement therapy and mortality among elderly U.S. women. Am J Epidemiol 2001; 153(2):145-152.
24. Petitti DB, Sidney S, Quesenberry Jr, CP et al.: Ischemic stroke and use of estrogen and estrogen/progesterone as hormone replacement therapy. Stroke 1998; 29(1):23-28.
25. Longstreth WT, Nelson LM, Koepsell TD, et al.: Subarachnoid hemorrhage and hormonal factors in women: A population-based case-control study. Ann Intern Med 1994; 121(3):168-173.
26. Grodstein F, Manson JE, Colditz GA, et al., A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133(12):933-941.
27. Hoibraaten E, Qvigstad E, Arnesen H, et al.: Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Results of the randomized, double blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84:961-967.
28. Lemaitre RN, Heckbert SR, Psaty BM, et al.: Hormone replacement therapy and associated risk of stroke in postmenopausal women. Arch Intern Med 2002; 162:1954-1960.
29. Laya MB, Gallagher JC, Schreiman JS, et al.: Effect of postmenopausal hormone replacement therapy on mammographic density and parenchymal pattern. Radiology. 1995; 196:433-437.
30. Greendale GA, Regoussin BA, Sie A, et al.: Effects of estrogen and estrogen progestin on mammographic parenchymal density. Ann Intern Med 1999; 130:262-269.
31. Oza AM, Boyd NF: Mammographic parenchymal patterns: A marker for breast cancer risk. Epidemiol Rev 1993; 15:196-208.
32. Warner E, Lockwood G, Trichler D, et al.: The risk of breast cancer associated with mammographic parenchymal patterns: A meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect Prev 1991; 16:67-72.
33. Chen CL, Weiss NS, Newcomb P, et al.: Hormone replacement therapy in relation to breast cancer. JAMA 2002; 287(6):734-741.
34. Rutter CM, Mandelson MT, Laya MB, et al.: Changes in breast density associated with itiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001; 285:171-176.
35. Boyack M, Lookinland S, Chasson, S: Efficacy of raloxifene in the treatment of menopause: A systematic review. J Am Acad Nurs Pract, 2002; 14(4):154-168.
36. Sillero-Arenas M, Delgado-Rodriguez M, Rodogies-Canteras R, et al.: Menopausal hormone replacement therapy and breast cancer: A meta-analysis. Obstet Gynecol 1992: 79(2):286-294.
37. Colditz GA, Egan KM, Stampfer JM: Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Am J Obstet Gynecol 1993; 168(5):1473-1480.
38. Steinberg KK, Smith SJ, Thacker SB, et al.: Breast cancer risk and duration of estrogen use: The role of study design in meta-analysis. Epidemiology 1994; 5(4):415-421.
39. Chen CL, Weiss NS, Newcomb P, et al.: Hormone replacement therapy in relation to breast cancer. JAMA 2002; 287(6):734-741.
40. Colditz GA, Hankinson SE, Hunter DJ, et al.: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332(24):1589-1593.
41. Ettinger B, Friedman GD, Bush T, et al.: Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996; 87(1):6-12.
42. Schairer C, Gail M, Byrne C, et al.: Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999; 91(3):264-270.
43. Willis DB, Calle EE, Maracle-McMahill HL, et al.: Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes & Control 1996; 7(4):449-457.
44. Hulley S, Furberg C, Barrett-Connor E, et al.: Norcardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow up (HERS II). JAMA 2002; 288:58-66.
45. Lane DA, Grant PJ: Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95:1517-1532.
46. Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, et al.: Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study. BMJ 1997; 314(7083):796-800.
47. Daly E, Vessey MP, Hawkins MM, et al.: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348(9033):977-980.
48. Daly E, Vessey MP, Painter R, et al.: Case-control study of venous thromboembolism risk in users of hormone replacement therapy [letter]. Lancet 1996; 348(9033):1027.
49. Jick H, Derby LE, Myers MW, et al.: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348(9033):981-983.
50. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, et al.: Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: A population-based study in southern Europe. Am J Epidemiol 1998; 147(4):387-390.
51. Hoibraaten E, Abdelnoor M, Sandset PM: Hormone replacement therapy with estradiol and risk of venous thromboembolism: A population based case control study. Thromb Haemost 1999; 82(4):1218-1221.
52. Grodstein F, Stampfer MJ, Goldhaber SZ, et al.: Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348(9033):983-987.
53. Chen CL, Weiss NS, Newcomb P, et al.: Hormone replacement therapy in relation to breast cancer. JAMA 2002; 287:734-741.
54. Gupta G, Aronow WS: Hormone replacement therapy: An analysis of efficacy based on evidence. Geriatrics 2002: 57(8):18-24.
55. Johnell O, Scheele WH, Lu Y, et al.: Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:985-992.
56. Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: Comparison between Alzheimer disease cases and nondemented control groups. Arch Neurol. 1994; 51:896-900.
57. Steffens DC, Norton MC, Plassman BL, et al. Enhanced cognitive performance with estrogen use in nondemented community-dwelling older women. J Am Geriatr Soc. 1999; 47:1171-1175.
58. Jacobs DM, Tang MX, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 1998; 50:368-373.
59. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women - The Women’s Health Initiative Memory Study: A randomized clinical trial. JAMA. 2003; 289(20):2651-2662.
60. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women - The Women’s Health Initiative Memory Study: A randomized clinical trial. JAMA. 2003; 289(20):2663-2672.
61. Nelson HD, Humphrey LL, Nygren P, et al.: Post menopausal hormone therapy. JAMA 2002; 288(7):872-881.
62. Reuters Medical News: Professional group issues new HRT guidelines. Available at:. Accessed October 15, 2002.
63. U. S. Preventive Services Task Force recommendations on HRT: Available at:. Accessed October 15, 2002.